Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.01 USD | +9.88% | -2.55% | +36.22% |
May. 23 | Cogent Reports Positive Cancer Combo Treatment Trial Data; Names Commercial Chief | MT |
May. 23 | Cogent Biosciences, Inc. Announces the Appointment of Cole Pinnow as Chief Commercial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.22% | 766M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- COGT Stock
- News Cogent Biosciences, Inc.
- Cogent Biosciences' Q4 Loss Narrows; Company Expects Cash Position to Fund Operations Into 2025